Dynamic conflicts in recurrent major depression: Does combined short-term psychotherapy and antidepressive medication lead to healthy dynamic functioning?

2017 ◽  
Vol 34 (1) ◽  
pp. 3-12 ◽  
Author(s):  
J. Christopher Perry ◽  
Prometheas Constantinides ◽  
Joshua Simmonds
Keyword(s):  
Major Depression ◽  
Short Term ◽  
Antidepressive Medication

Short-term prognosis in primary and secondary major depression

1985 ◽  
Vol 9 (3) ◽  
pp. 265-270 ◽  
Author(s):  
William Coryell ◽  
Mark Zimmerman ◽  
Bruce Pfohl
Keyword(s):  
Major Depression ◽  
Short Term

Tolerability of mirtazapine vs SSRIs in short term treatment of major depression

1999 ◽  
Vol 9 ◽  
pp. 229 ◽  
Author(s):  
C.M.E. Kremer ◽  
J.T.H. Helsdingen ◽  
J.A. Schutte ◽  
E. Vester
Keyword(s):  
Major Depression ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment

Correlates and Short-Term Course of Self-Poisoning in Adolescents

1996 ◽  
Vol 168 (1) ◽  
pp. 38-42 ◽  
Author(s):  
Michael Kerfoot ◽  
Elizabeth Dyer ◽  
Val Harrington ◽  
Adrine Woodham ◽  
Richard Harrington
Keyword(s):  
Clinical Trial ◽  
Major Depression ◽  
Mental Disorders ◽  
Family Background ◽  
Family Dysfunction ◽  
Treatment Trial ◽  
Short Term ◽  
Community Controls ◽  
Specific Association

BackgroundThe features of adolescents who had taken an overdose were assessed to determine the focus for a treatment trial.MethodOverdose cases were compared with psychiatric and community controls who had not taken an overdose in respect of mental disorders and family background.ResultsOverdose cases had high rates of major depression, but most of them recovered from depression within six weeks of the overdose. There was a specific association between taking an overdose and family dysfunction.ConclusionsFamily dysfunction could be a useful focus in a clinical trial of the aftercare of adolescents who have taken an overdose.

scholarly journals Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive–behavioural therapy in adolescents with major depression

2007 ◽  
Vol 191 (6) ◽  
pp. 521-527 ◽  
Author(s):  
Sarah Byford ◽  
Barbara Barrett ◽  
Chris Roberts ◽  
Paul Wilkinson ◽  
Bernadka Dubicka ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Major Depression ◽  
Cognitive Behavioural Therapy ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Clinical Care ◽  
Cost Effective ◽  
Behavioural Therapy ◽  
Short Term ◽  
Cognitive Behavioural

BackgroundMajor depression is an important and costly problem among adolescents, yet evidence to support the provision of cost-effective treatments is lacking.AimsTo assess the short-term cost-effectiveness of combined selective serotonin reuptake inhibitors (SSRIs) and cognitive–behavioural therapy (CBT) together with clinical care compared with SSRIs and clinical care alone in adolescents with major depression.MethodPragmatic randomised controlled trial in the UK. Outcomes and costs were assessed at baseline, 12 and 28 weeks.ResultsThe trial comprised 208 adolescents, aged 11–17 years, with major or probable major depression who had not responded to a brief initial psychosocial intervention. There were no significant differences in outcome between the groups with and without CBT. Costs were higher in the group with CBT, although not significantly so (P=0.057). Cost-effectiveness analysis and exploration of the associated uncertainty suggest there is less than a 30% probability that CBT plus SSRIs is more cost-effective than SSRIs alone.ConclusionsA combination of CBT plus SSRIs is not more cost-effective in the short-term than SSRIs alone for treating adolescents with major depression in receipt of routine specialist clinical care.

Cognitive symptoms in mayor depression: A study with vortioxetina

2017 ◽  
Vol 41 (S1) ◽  
pp. S538-S538
Author(s):  
O. Porta Olivares ◽  
M. Juncal Ruiz ◽  
B. Fernández Abascal Puente ◽  
M. Gómez Revuelta ◽  
M. Pérez Herrera ◽  
...  
Keyword(s):  
Major Depression ◽  
Short Term Memory ◽  
Cognitive Symptoms ◽  
Therapeutic Tool ◽  
Short Term ◽  
Symptoms Of Depression ◽  
Hearing Test ◽  
Previously Treated ◽  
Competing Interest ◽  
Significant Factors

IntroductionThe major depression is associated with decreased cognitive functions in a range of areas, including attention, memory and executive functions. The cognitive symptoms of depression can have a profound effect on the ability of patients to keep out the tasks of daily living, and are significant factors that affect the ability to function both interpersonal and occupational level.AimsVortioxetina have a multimodal action acting on various serotonin receptors in addition to inhibiting serotonin reuptake. Vortioxetina, is a new therapeutic tool seems to have shown efficacy in the treatment of cognitive symptoms of depression.MethodsTo evaluate this action we have evaluated the cognitive decline in patients with major depression before receiving treatment vortioxetina (whether state or not previously treated with other antidepressants) and at 2, 6 and 12 months after starting treatment with the drug. For that, we’ve used the Verbal Hearing Test King (RAVLT), which evaluates the auditory verbal short-term memory, the learning rate, the retention of information, and the differences between learning and recovery, and testing Digit substitution by symbols (DSST) that perform quick detection of brain dysfunctions by a conventional task.ResultsThe results of this study are still under analysis.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sign in / Sign up

Export Citation Format

Share Document